Evaluation of apoptosis regulatory proteins in response to PUVA therapy for psoriasis

Photodermatology Photoimmunology and Photomedicine

Volumn 29, Issue 1, 2013, Pages 18-26

  El Domyati, Moetaz ^a   Moftah, Noha H ^a   Nasif, Ghada A ^a   Abdel Wahab, Hossam M ^a   Barakat, Manal T ^a   Abdel Aziz, Rasha T ^a  

^a MINIA UNIVERSITY   (Egypt)

Author keywords

Apoptosis; Bcl 2; P53; Psoriasis; PUVA

Indexed keywords

FAS ANTIGEN; PEROXIDASE; PROTEIN BAX; PROTEIN BCL 2; PROTEIN P53;

ADULT; ARTICLE; CLINICAL ARTICLE; FEMALE; HISTOMETRY; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IMMUNOPEROXIDASE STAINING; KERATINOCYTE; MALE; NICK END LABELING; PRIORITY JOURNAL; PROTEIN EXPRESSION; PSORIASIS VULGARIS; PUVA; SKIN BIOPSY; SKINFOLD THICKNESS;

ADULT; APOPTOSIS; APOPTOSIS REGULATORY PROTEINS; FEMALE; GENE EXPRESSION REGULATION; HUMANS; KERATINOCYTES; MALE; MIDDLE AGED; PSORIASIS; PUVA THERAPY; TIME FACTORS;

EID: 84871897288     PISSN: 09054383     EISSN: 16000781     Source Type: Journal    
DOI: 10.1111/phpp.12012     Document Type: Article

References (50)

1. Mehlis SL, Gordon KB. The immunology of psoriasis and biologic immunotherapy. J Am Acad Dermatol 2003; 49: 44-50.
2. Laporte M, Galand P, Fokan D, De Graef C, Heenen M. Apoptosis in established and healing psoriasis. Dermatology 2000; 200: 314-316.
3. Raskin CA. Apoptosis and cutaneous biology. J Am Acad Dermatol 1997; 36: 885-896.
4. Liang S, Ohtsuki Y, Furihata M etal. Sun exposure and aging-dependent p53 protein accumulation results in growth advantage for tumor cells in carcinogenesis of non-melanocytic skin cancer. Virchows Arch 1999; 434: 193-199.
5. Timmer T, De Vries EG, De Jong S. Fas receptor-mediated apoptosis: a clinical application? J Pathol 2002; 196: 125-134.
6. Kuwana T, Bouchier-Hayes L, Chipuk JE etal. BH3 domains of BH3-only proteins differentially regulate Bax-mediated mitochondrial membrane permeabilization both directly and indirectly. Mol Cell 2005; 17: 525-535.
7. Nicholas JL, Viadislav C, Hani G. Photochemotherapy: general principles. Clin Dermatol 1997; 15: 745-752.
8. Johnson R, Staiano-Coico L, Austin L, Cardinale I, Nabeya-Tsukifuji R, Krueger JG. PUVA treatment selectively induces a cell cycle block and subsequent apoptosis in human T-lymphocytes. Photochem Photobiol 1996; 63: 566-571.
9. British Photodermatology Group. British Photodermatology Group guidelines for PUVA. Br J Dermatol 1994; 130: 246-255.
10. Fredriksson T, Pettersson U. Severe psoriasis-oral therapy with a new retinoid. Dermatologica 1978; 157: 238-244.
11. Yildiz L, Baris S, Senturk N, Kandemir B. Over-expression of Bcl-2 in lymphocytes of psoriatic skin. J Eur Acad Dermatol Venereol 2003; 17: 538-540.
12. Kikuchi A, Nishikawa T. Apoptotic and proliferating cells in cutaneous lymphoproliferative diseases. Arch Dermatol 1997; 133: 829-833.
13. Schleyer V, Landthaler M, Szeimies RM. Novel pharmacological approaches in the treatment of psoriasis. J Eur Acad Dermatol Venereol 2005; 19: 1-20.
14. Takahashi H, Manabe A, Ishida-Yamamoto A, Hashimoto Y, Lizuka H. Aberrant expression of apoptosis-related molecules in psoriatic epidermis. J Dermatol Sci 2002; 28: 187-197.
15. Gunduz K, Demireli P, Vatansever S, Inanir I. Examination of Bcl-2 and p53 expressions and apoptotic index by TUNEL method in psoriasis. J Cutan Pathol 2006; 33: 788-792.
16. Hannuksela-Svahn A, Paakko P, Auito P, Reunala T, Karvonen J, Vahakangas K. Expression of P53 protein before and after PUVA treatment in psoriasis. Acta Derm Venereol 1999; 79: 195-199.
17. El-Domyati M, Barakat M, Abdel-Razek R. Expression of apoptosis regulating proteins, P53 and Bcl-2, in psoriasis. J Egypt Wom Dermatol Soc 2006; 3: 46-50.
18. Yazici AC, Karabulut AA, Özen O, Eksiolu M, Üstun H. Expression of p53 in lesions and unaffected skin of patients with plaque-type and guttate psoriasis: a quantitative comparative study. J Dermatol 2007; 34: 367-374.
19. Baran W, Szepietowski JC, Szybejko-Machaj G. Expression of P53 protein in psoriasis. Acta Dermatovenerol Alp Panonica Adriat 2005; 14: 79-83.
20. El-Domyati M, Attia S, Saleh F etal. Expression of p53 in normal sun-exposed and protected skin (type IV- V) in different decades of age. Acta Derm Venereol 2003; 83: 98-104.
21. El-Domyati M, Moftah NH, Nasif GA, Abdel-Wahab HM, Abdel-Razek RT, El-Din WH. Overexpression of proapoptotic proteins, Fas, and Bax after topical calcipotriol therapy for psoriasis. J Egypt Wom Dermatol Soc 2011; 9: 38-46.
22. Gilhar A, Yaniv R, Assy B, Serafimovich S, Ullmann Y, Kalish RS. Fas pulls the trigger on psoriasis. Am J Pathol 2006; 168: 170-175.
23. Wrone-Smith T, Johnson T, Nelson B etal. Discordant expression of Bcl-xL and Bcl-2 by keratinocytes in vitro and psoriatic keratinocytes in vivo. Am J Pathol 1995; 146: 1079-1088.
24. Kocak M, Bozodogan O, Erkek E, Atasoy P, Birol A. Examination of Bcl-2, Bcl-X and Bax protein expression in psoriasis. Int J Dermatol 2003; 42: 789-793.
25. Batinac T, Zamolo G, Hadzisejdic I etal. Expression of Bcl-2 family proteins in psoriasis. Croat Med J 2007; 48: 319-326.
26. Tomkova H, Fujimoto W, Arata J. Expression of the Bcl-2 homologue Bax in normal human skin, psoriasis vulgaris and non-melanoma skin cancers. Eur J Dermatol 1998; 8: 256-260.
27. Hockenbery D, Nunez G, Milliman C, Schreiber RD, Korsmeyer SJ. Bcl-2 is an inner mitochondrial membrane protein that blocks programmed cell death. Nature 1990; 348: 334-336.
28. El-Domyati M, Barakat M, Abdel-Razek R, Anbar TE. Apoptosis, P53 and Bcl-2 expression in response to topical calcipotriol therapy for psoriasis. Int J Dermatol 2007; 46: 468-474.
29. Qin LY, Xing WB, Ye WJ. Effect of combined therapy with Chinese drug and narrow broad ultraviolet B on Bcl-2, caspase-3 and survivin in skin lesion with psoriasis vulgaris. Zhongguo Zhong Xi Yi Jie He Za Zhi 2010; 30: 706-709.
30. Bal N, Tuncer I, Baba M, Bolat F. Bcl-2 expression in dermal lymphocytes in lichen planus and psoriasis vulgaris. J Eur Acad Dermatol Venereol 2008; 22: 616-650.
31. Lu QL, Poulson R, Wong L, Hanby AM. Bcl-2 expression in adult and embryonic non-hemopoietic tissues. J Pathol 1993; 169: 431-437.
32. Kastelan M, Prpić-Massari L, Brajac I. Apoptosis in psoriasis. Acta Dermatovenerol Croat 2009; 17: 182-186.
33. Heenen M, Simonart T. Apoptosis in psoriatic epidermis. J Cutan Pathol 2008; 35: 346.
34. Canton M, Caffieri S, Dall'Acqua F, Di Lisa F. PUVA-induced apoptosis involves mitochondrial dysfunction caused by the opening of the permeability transition pore. FEBS Lett 2002; 522: 168-172.
35. Weatherhead SC, Farr PM, Jamieson D etal. Keratinocyte apoptosis in epidermal remodeling and clearance of psoriasis induced by UV radiation. J Invest Dermatol 2011; 131: 1916-1926.
36. Ragaz A, Ackerman A. Evolution, maturation and regression of lesions of psoriasis. New observations and correlation of clinical and histologic findings. Am J Dermatopathol 1979; 1: 199-214.
37. Viola G, Fortunato E, Cecconet L, Del Giudice L, Dall'Acqua F, Basso G. Central role of mitochondria and p53 in PUVA-induced apoptosis in human keratinocytes cell line NCTC-2544. Toxicol Appl Pharmacol 2008; 227: 84-96.
38. Leverkus M, Yaar M, Gilchrest BA. Fas/Fas ligand interaction contributes to UV-induced apoptosis in human keratinocytes. Exp Cell Res 1997; 232: 255-262.
39. El Hadidi H, Huntar N, Zayed A etal. The effect of PUVA phototherapy on Bcl-2 expression in psoriasis vulgaris. J Egypt Wom Dermatol Soc 2008; 5: 65-68.
40. Bang B, Rygaard J, Baadsgaard O, Skov L. Increased expression of Fas on human epidermal cells after in vivo exposure to single-dose ultraviolet (UV) B or long-wave UVA radiation. Br J Dermatol 2002; 147: 1199-1206.
41. Hönigsmann H. Phototherapy for psoriasis. Clin Exp Dermatol 2001; 6: 343-350.
42. Bulat V, Situm M, Dediol I, Ljubicić I, Bradić L. The mechanisms of action of phototherapy in the treatment of the most common dermatoses. Coll Antropol 2011; 35 (Suppl): 147-151.
43. Santamaria AB, Davis DW, Nghiem DX etal. P53 and Fas ligand are required for psoralen and UVA induced apoptosis in mouse epidermal cells. Cell Death Differ 2002; 9: 549-560.
44. Bennett M, Macdonald K, Chan SW, Luzio JP, Simari R, Weissberg P. Cell surface trafficking of Fas: a rapid mechanism of p53-mediated apoptosis. Science 1998; 282: 290-293.
45. Stern RS, Lunder AJ. Risk of squamous cell carcinoma and methoxsalen (Psoralen) and UVA radiation (PUVA): a meta-analysis. Arch Dermatol 1998; 134: 1582-1585.
46. Fung CY, Fisher DE. P53: from molecular mechanisms to prognosis in cancer. J Clin Oncol 1995; 13: 808-811.
47. Li G, Tron V, Ho V. Induction of squamous cell carcinoma in P-53-deficient mice after ultraviolet irradiation. J Invest Dermatol 1998; 110: 72-75.
48. Ren Z, Ponten F, Nisler M, Ponten J. Two distinct P53 immunohistochemical patterns in human squamous cell skin cancer, precursors and normal epidermis. Int J Cancer 1996; 69: 174-179.
49. Nataraj AJ, Wolf P, Cerroni L, Ananthaswamy HN. P53 mutation in squamous cell carcinomas from psoriasis patients treated with psoralen+UVA (PUVA). J Invest Dermatol 1997; 109: 238-243.
50. Seidl H, Kreimer-Erlacher H, Bäck B etal. Ultraviolet exposure as the main initiator of p53 mutations in basal cell carcinomas from psoralen and ultraviolet A-treated patients with psoriasis. J Invest Dermatol 2001; 117: 365-370.